Clinical Trial Detail

NCT ID NCT02620800
Title Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications

pancreatic adenocarcinoma

Therapies

Bevacizumab + Fluorouracil + Leucovorin + Nab-paclitaxel + Oxaliplatin

Age Groups: adult

No variant requirements are available.